Patient Guide: A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 460 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT04636814
Status: ACTIVE_NOT_RECRUITING
Condition: Chronic Obstructive Pulmonary Disease
Phase: PHASE3

Find a Study Location Near You

This study is available at 460 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Andalusia, Alabama
  • Foley, Alabama
  • Guntersville, Alabama
  • • And 457 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily